• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

How to safe­ly and suc­cess­ful­ly speed your in­jectable in­to the clin­ic

3 years ago

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

3 years ago

The Fac­tors Dri­ving a Rapid Evo­lu­tion of Gene & Cell Ther­a­py and CAR-T Clin­i­cal Re­search in APAC

3 years ago

A bet­ter way to ex­plore TC­GA da­ta

3 years ago

Ac­cel­er­at­ing To­ward Hu­man Rel­e­vant Non­clin­i­cal Test Meth­ods

3 years ago

Will Com­mu­ni­cat­ing with Per­son­al HCPs Get the In­dus­try Clos­er to More Di­verse and Ful­ly En­rolled Clin­i­cal Tri­als?

3 years ago

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

3 years ago

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

3 years ago

Ad­dress­ing the ‘Ca­pac­i­ty Crunch’ with a Scal­able Plat­form Process Ap­proach

3 years ago

Are we clos­er than we think to per­son­al­ized ge­net­ic med­i­cine?

3 years ago

M&A: a crit­i­cal dri­ver for sus­tain­able top-line growth in health­care

3 years ago

Health eq­ui­ty in­no­va­tion must go be­yond the sci­ence

3 years ago

Lead­ing a Rev­o­lu­tion in Can­cer Care Means Fac­ing Health Eq­ui­ty Chal­lenges

3 years ago

Op­ti­miz­ing Cell and Gene Ther­a­py De­vel­op­ment and Pro­duc­tion: How Tech­nol­o­gy Providers Like Corn­ing Life Sci­ences are Spurring In­no­va­tion

3 years ago

Biotech in­vestors: how to find val­ue in a bear mar­ket

4 years ago

Process Plat­forms vs. Cus­tom Process De­vel­op­ment for AAVs and Gene Ther­a­pies

4 years ago

De­cen­tral­iza­tion: An Eth­i­cal Oblig­a­tion

4 years ago

Avoid­ing Cell Ther­a­py Man­u­fac­tur­ing Grid­locks — a Do’s and Don’ts Guide

4 years ago

Mea­sur­ing Re­al-World Sleep with Actig­ra­phy: Three Clin­i­cal Tri­al Use Cas­es

4 years ago

Biotech Out­look 2022: Am­ple Op­por­tu­ni­ty for a Re­bound

4 years ago

The dawn of ven­ture cap­i­tal-backed cryo-EM star­tups

4 years ago

Cen­tral­ize Clin­i­cal Tri­als with De­cen­tral­ized Clin­i­cal Tri­als

4 years ago

The four steps FU­JI­FILM Diosynth Biotech­nolo­gies is tak­ing to im­pact the fu­ture of bio­phar­ma man­u­fac­tur­ing

4 years ago

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

4 years ago
First page Previous page 2345678 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times